QGC011 - Hypertension in combination

A synergic effect of bapais in association with other anti-hypertensive compounds

Because a combination of treatments is generally necessary to control patients’ blood pressure, Quantum Genomics intends to develop and test the clinical efficacy of combinations combining a BAPAI product with other antihypertensive agents.

Quantum Genomics has already demonstrated in hypertensive rats the therapeutic value of combining BAPAI with antihypertensive drugs acting on the peripheral renin-angiotensin system such as angiotensin converting enzyme inhibitors (ACE inhibitors) or angiotensin II type 1 receptor antagonists (ARAs).

Quantum Genomics selected QGC011, which combienes firibastat with an CEI and showed in hypertensive rats that the hypotensive effect induced by QGC011 is significantly greater than the hypotensive effect of each compound administered separately.